rhIL-7-hyFc(一种长效白细胞介素-7)提升 CAR-T 细胞治疗实体瘤的疗效
rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors.
本研究为 NT-I7 联合 CAR-T 细胞治疗人类实体瘤提供了依据。
64.4分
★★★☆☆
FRONTIER PAPERS
rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors.
本研究为 NT-I7 联合 CAR-T 细胞治疗人类实体瘤提供了依据。
Determination of high-grade serous ovarian cancer stem cell-based subtypes and prognostic model and identification of highly expressed VSIG4 and STAB1
结果为了解预后预测和治疗反应提供了新的见解,并确定VSIG4和STAB1是影响HGSOC中巨噬细胞的潜在生物标志物。
共 2 条
MEMBER ACCOUNT
登录成功会直接打开下一页。